Video Thumbnail

How the Hydrus Microstent could change the world of glaucoma care

Years ago, we heard a fascinating tale of the Hydrus Microstent’s competitive advantages. At the same time, parent company Ivantis seemed like a small company with only a shot at going big. Now, the company has been acquired by Alcon. In talking with Cari Stone, Alcon’s Vice President of Global Glaucoma, it felt like a great bookend to a tale of big glaucoma care aspirations that were indeed realized.

Notify of
Inline Feedbacks
View all comments